Citi analyst Yigal Nochomovitz lowered the firm’s price target on Arcus Biosciences (RCUS) to $44 from $56 and keeps a Buy rating on the shares after the company announced that the Phase 3 STAR-221 trial has been discontinued due to futility observed at a pre-specified interim analysis. Following the news, the firm has removed domvanalimab plus zimberelimab in gastric-related indications from its valuation, but remains positive on casdatifan ahead of readouts in 2026, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Arcus Biosciences: Strategic Shift to Casdatifan with Strong Financial Position and Buy Rating
- Arcus Biosciences price target lowered to $30 from $39 at Truist
- Arcus Biosciences: Strategic Focus and Financial Positioning Drive Buy Rating
- Arcus Biosciences price target raised to $32 from $28 at H.C. Wainwright